Drug Penetrance of Veliparib and Carboplatin in TNBC Drug Penetrance of Veliparib and Carboplatin in TNBC

Researchers investigate whether non-response to chemotherapy in TNBC is due to insufficient drug penetration.Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None Journal Article Source Type: news

Related Links:

DESTINY-Breast04 to evaluate [fam-] trastuzumab deruxtecan (DS-8201) versus investigator's choice in HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy No anti-HER2 therapies are currently approved for H... Biopharmaceuticals, Oncology Daiichi Sankyo, trastuzumab, breast cancer, HER2
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Four months ago I was diagnosed with breast cancer. Since then, I’ve had biopsies, a mastectomy, lymph node removals, countless scans and blood tests, an imminent death scare and two rounds of chemotherapy. Today, I’ll be having my third round and by rights I should be feeling terrified. Chemo’s pretty toxic – my oncologist told me semi-jokingly that the aim is to get as close to killing me as possible. But I don’t feel scared – I’m feeling calm and secure. This is because, thanks to the NHS team at south London’s St George’s hospital, a trip to the chemo ward feels as ...
Source: UNISON Health care news - Category: UK Health Authors: Tags: Article Magazine cancer NHS Source Type: news
The Opti-HER HEART trial examined whether liposomal formulations of chemotherapy agents may reduce cardiac toxicity in HER2+ breast cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Autophagy played a significant role in the stemness maintenance and was a key mechanism underlying the survival against chemotherapy in epithelial ovarian cancer stem cells (EOCSCs). Breast cancer 1 (BRCA1) could regulate drug resistance of EOCSCs through autophagy. Meanwhile, changes in the level of autophagy provided feedback regarding the expression of BRCA1. AbstractBreast cancer 1 (BRCA1) and autophagy both play a significant role in drug resistance. However, little is known about the dynamic cross talk between BRCA1 and autophagy in the regulation of drug sensitivity. Here, we investigated the drug resistance ‐asso...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Publication date: Available online 10 January 2019Source: Reproductive BioMedicine OnlineAuthor(s): Matteo Lambertini, Massimo Di Maio, Francesca Poggio, Olivia Pagani, Giuseppe Curigliano, Lucia Del Mastro, Shani Paluch-Shimon, Sibylle Loibl, Ann H. Partridge, Jr. Hatem A. Azim, Fedro A. Peccatori, Isabelle DemeestereABSTRACTResearch questionWe explored the knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer (BC) patients.DesignPhysicians attending two international BC conferences were asked to complete a 26-item questionnaire exploring fertili...
Source: Reproductive BioMedicine Online - Category: Reproduction Medicine Source Type: research
AbstractPurposeBRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize thatBRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy.MethodsWe included women with primary breast cancers screened forBRCA1/BRCA2 germline mutations and treated with (neo)adjuvant chemotherapy in Geneva (Swiss cohort). The primary endpoint was the incidence of febrile neutropenia following the first chemotherapy cycle (C1). Secondary endpoints were the incidence of grade 3 –4 neutropenia, grade 4 neutropenia and hospitalization durin...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Condition:   HER-2 Negative Breast Cancer Intervention:   Drug: Chemotherapy Sponsor:   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study confirmed the survival advantage of adjuvant radiotherapy for the triple ‐negative breast cancer (TNBC) patients. These results may optimize the current individualized treatment decisions for this patient population. AbstractObjectivesThe value of adjuvant radiotherapy for triple ‐negative breast cancer (TNBC) has been controversial recently. This study aims to clarify the influence of radiotherapy on the survival of TNBC patients after surgery based on a large population analysis.MethodsThe Surveillance, Epidemiology, and End Results (SEER) database was exploited to select eligible patients from 2010 to 201...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
AbstractPurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23  months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [hazard ratio (HR) 0.58;P 
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck, was originally published electronically on the publisher &rsq...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health